Skip to content
Menu
GHK-Cu Safe

GHK-Cu safety questions, answered only from peer-reviewed work.

GHK-Cu hair research

An adult gently gathering naturally graying hair off the neck, seen from behind.

The main human hair-count result concerns a combination containing free GHK. Keeping that distinction visible prevents a promising experiment from becoming a claim about GHK-Cu alone.

The human combination trial

In the 2016 trial by Lee and colleagues, 45 men with male-pattern hair loss were followed for six months. The tested topical preparation combined 5-aminolevulinic acid with GHK, the peptide without copper. A comparison group received a lotion without the active combination.

Hair counts increased more in the active groups than in the comparison group. Hair thickness did not show the same improvement, and the researchers reported no adverse events. Those are useful observations about the tested preparation over the study period.

The study cannot establish which ingredient produced the change or whether the combination was necessary. It also cannot show that standalone GHK-Cu would produce the same result. Describing it as a trial proving that copper peptide regrows hair would omit the preparation the investigators actually tested.

A study with 45 participants has limited ability to detect uncommon harms. Its lack of reported adverse events is part of the result, rather than a general safety assurance. Larger and longer trials of clearly specified preparations would make the evidence more useful.

The 2007 isolated-follicle experiment tested AHK-Cu. That copper peptide has a different amino-acid sequence from GHK-Cu. Researchers examined human hair follicles outside the body and cultured dermal papilla cells, which are involved in follicle function.

The work reported follicle elongation and changes in cell survival under the tested conditions. It helps explain interest in copper-peptide research. It does not establish a human scalp treatment, because an isolated follicle lacks the exposure conditions and wider biology of a person.

The different name is substantive. Substituting GHK-Cu for AHK-Cu in a summary would change the experiment. Related compounds can provide a rationale for further investigation while leaving the main clinical question unanswered.

What mouse delivery work adds

A microemulsion study involving GHK-Cu examined a specialized topical delivery system and hair-related outcomes in mice. A microemulsion is a mixture designed to carry ingredients through a medium; its composition affects the exposure being tested.

The researchers observed effects on the hair growth cycle in that animal setting. The finding belongs to the peptide, carrier, species, and conditions together. It cannot establish the performance of a different human scalp product or settle a comparison with established hair-loss care.

Delivery work is relevant because the skin barrier can limit exposure. Improving delivery also changes the safety question: more access to tissue is a reason to measure tolerability and exposure carefully, rather than assume that a stronger laboratory response guarantees a better practical result.

The skin research page explains this distinction in more detail. A carrier result and a peptide result may be connected, but they are not interchangeable evidence.

Hair count, pigment, and safety

Hair growth and hair color are different outcomes. The palmitoyl copper-peptide pigment paper used human and mouse melanoma cell lines with acetyl tyrosine. It did not test gray-hair reversal in people, and it did not measure hair regrowth.

Personal accounts of less shedding or thicker-looking hair also circulate in research and skincare communities. These are anecdotal reports. Other products and changes in care can occur at the same time, so the reports cannot establish what caused a perceived change.

The useful questions are specific: which preparation was tested, did investigators count hairs or measure thickness, how long were participants observed, and how were reactions recorded? Answers from one small combination trial do not define the safety of other topical preparations or of systemic GHK-Cu.

The effects page considers irritation and pigment separately. The dosage page gives the trial's concentrations as study conditions, without treating them as instructions for a different substance or route.